News articles about Fibrocell Science (NASDAQ:FCSC) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fibrocell Science earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.1170849278996 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Fibrocell Science (NASDAQ FCSC) traded down 3.45% during midday trading on Friday, reaching $2.66. 9,081 shares of the company traded hands. Fibrocell Science has a 12 month low of $0.52 and a 12 month high of $4.64. The firm’s market capitalization is $39.15 million. The company has a 50 day moving average of $3.25 and a 200 day moving average of $2.37.
Fibrocell Science (NASDAQ:FCSC) last issued its earnings results on Wednesday, August 9th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. On average, equities research analysts predict that Fibrocell Science will post ($2.30) earnings per share for the current fiscal year.
Several equities research analysts recently commented on FCSC shares. Zacks Investment Research lowered shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $5.70 price target on shares of Fibrocell Science in a research note on Friday, June 9th.
TRADEMARK VIOLATION WARNING: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/08/26/fibrocell-science-fcsc-given-daily-coverage-optimism-score-of-0-06.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.
